HomeAMG • ETR
add
Amgen Inc
Previous close
€241.45
Day range
€239.60 - €241.20
Year range
€230.75 - €318.05
Market cap
149.01B USD
Avg Volume
423.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 8.15B | 9.43% |
Operating expense | 3.20B | 0.47% |
Net income | 1.73B | 1,630.97% |
Net profit margin | 21.23 | 1,496.71% |
Earnings per share | 4.90 | 23.74% |
EBITDA | 3.52B | 19.29% |
Effective tax rate | 12.32% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 8.81B | -9.25% |
Total assets | 89.37B | -3.89% |
Total liabilities | 83.16B | -5.45% |
Total equity | 6.21B | — |
Shares outstanding | 537.71M | — |
Price to book | 20.92 | — |
Return on assets | 6.46% | — |
Return on capital | 8.98% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 1.73B | 1,630.97% |
Cash from operations | 1.39B | 101.89% |
Cash from investing | -447.00M | -105.99% |
Cash from financing | -4.11B | -140.46% |
Net change in cash | -3.16B | -155.91% |
Free cash flow | 1.21B | -34.48% |
About
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp Wikipedia
Founded
Apr 8, 1980
Headquarters
Website
Employees
28,000
